Dr. Swiedler is a biotechnology consultant with more than 25 years of experience in the biotechnology field, primarily as a scientist and junior executive at Glycomed, Inc., and as a clinical scientist and senior executive at BioMarin Pharmaceutical, Inc. Over a 10-year period at BioMarin, he contributed to both the non-clinical and clinical aspects of drug development for the regulatory approvals of the orphan drugs Aldurazyme, Naglazyme and Kuvan. He continues to focus on orphan drug products for genetic diseases, working with both biotech companies and investment firms. Dr. Swiedler received his BS degree from the University at Albany, and his M.D. and Ph.D. degrees from the Johns Hopkins University. He completed residency in Anatomic Pathology at Yale University School of Medicine and Duke University School of Medicine, as well as a post-doctoral fellowship at Duke.
